The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
The role of HER2 in cancer therapy and targeted drug delivery
Open accessAbstract
HER2 is highly expressed in a significant proportion of breast cancer, ovarian cancer, and gastric cancer. Since the discovery of its role in tumorigenesis, HER2 has received great attention in cancer research during the past two decades. Successful development of the humanized monoclonal anti-HER2 antibody (Trastuzumab) for the treatment of breast cancer further spurred scientists to develop various HER2 specific antibodies, dimerization inhibitors and kinase inhibitors for cancer therapy. On the other hand, the high expression of HER2 and the accessibility of its extracellular domain make HER2 an ideal target for the targeted delivery of anti-tumor drugs as well as imaging agents. Although there is no natural ligand for HER2, various artificial ligands targeting HER2 have been developed and applied in various targeted drug delivery systems. The emphasis of this review is to elucidate the roles of HER2 in cancer therapy and targeted drug delivery. The structure and signal pathway of HER2 will be briefly described. The role of HER2 in tumorigenesis and its relationship with other tumor markers will be discussed. For the HER2 targeted cancer therapy, numerous strategies including the blockage of receptor dimerization, inhibition of the tyrosine kinase activity, and interruption of the downstream signal pathway will be summarized. For the targeted drug delivery to HER2 positive tumor cells, various targeting ligands and their delivery systems will be described in details.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Role of angiogenesis in tumor growth and metastasis
FOLKMAN, J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70065-1 · Cited by 2,400
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
The cell-cell adhesion molecule E-cadherin
van Roy, F., & Berx, G. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8281-1 · Cited by 1,325
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009) · Clinical Medicine & Research · doi:10.3121/cmr.2008.825 · Cited by 765
Phosphotyrosine interactome of the ErbB‐receptor kinase family
Schulze, W. X., Deng, L., & Mann, M. (2005) · Molecular Systems Biology · doi:10.1038/msb4100012 · Cited by 753
A quantitative protein interaction network for the ErbB receptors using protein microarrays
Jones, R. B., Gordus, A., Krall, J. A., & MacBeath, G. (2006) · Nature · doi:10.1038/nature04177 · Cited by 727
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 622
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 613
Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
Pietras, R. J., Arboleda, J., Dm, R., Wongvipat, N., Pegram, M. D., Ramos, L., Cm, G., Mg, P., Sliwkowski, M. X., & Dj, S. (1995) · PubMed · Cited by 603
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Yeh, S., Lin, H.-K., Kang, H.-Y., Thin, T. H., Lin, M.-F., & Chang, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5458 · Cited by 594
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
Li, Y. M., Pan, Y., Wei, Y., Cheng, X., Zhou, B. P., Tan, M., Zhou, X., Xia, W., Hortobagyi, G. N., Yu, D., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.027 · Cited by 537
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Rubin, I., & Yarden, Y. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s3 · Cited by 500
Pietras, R. J., FENDLY, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994) · PubMed · Cited by 437
Sastre‐Garau, X., Jouve, M., Asselain, B. J. R., Vincent‐Salomon, A., Beuzeboc, P., Dorval, T., Durand, J. C., Fourquet, A., & Pouillart, P. (1996) · Cancer · Cited by 423
E-cadherin expression in primary carcinomas of the breast and its distant metastases
Kowalski, P. J., Rubin, M. A., & Kleer, C. G. (2003) · Breast Cancer Research · doi:10.1186/bcr651 · Cited by 414
Silencing of CXCR4 Blocks Breast Cancer Metastasis
Liang, Z., Yoon, Y., Votaw, J., Goodman, M. M., Williams, L., & Shim, H. (2005) · Cancer Research · doi:10.1158/0008-5472.967.65.3 · Cited by 402
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
Signoretti, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1918 · Cited by 397
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., & Sasaki, T. (1991) · PubMed · Cited by 375
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344
Trastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
Parise, C. A., Bauer, K. R., Brown, M. M., & Caggiano, V. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00822.x · Cited by 331
Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C. R., HARRIS, R. A., Pagé, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., et al. (2001) · PubMed · Cited by 330
Konecny, G. E., Meng, Y. G., Untch, M., Wang, H.-J., Bauerfeind, I., Epstein, M., Stieber, P., Vernes, J.-M., Gutierrez, J., Hong, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0951-3 · Cited by 318
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Lee, D.-F., Bartholomeusz, G., Ou-Yang, F., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.012 · Cited by 305
The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes
Mendrola, J. M., Berger, M. B., King, M. C., & Lemmon, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108681200 · Cited by 303
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Williams, C. C., Allison, J. G., Vidal, G. A., Burow, M. E., Beckman, B. S., Marrero, L., & Jones, F. E. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403155 · Cited by 263
A putative molecular-activation switch in the transmembrane domain of erbB2
Fleishman, S. J., Schlessinger, J., & Ben-Tal, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252640799 · Cited by 262
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family
Hsu, S.-C., & Hung, M.-C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610014200 · Cited by 260
Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin
Wong, A. S. T., & Gumbiner, B. M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200212033 · Cited by 260
Xia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
The epidermal growth factor receptor family
Bazley, L. A., & Gullick, W. J. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01032 · Cited by 250
Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor
Giri, D. K., Ali-Seyed, M., Li, L.-Y., Lee, D.-F., Ling, P., Bartholomeusz, G., Wang, S.-C., & Hung, M.-C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11005-11018.2005 · Cited by 244
Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells
Oh, A. S., Lorant, L. A., Holloway, J. N., Miller, D. L., Kern, F. G., & El-Ashry, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.8.0678 · Cited by 226
Tolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandström, M., Rosik, D., Carlsson, J., Lundqvist, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1630 · Cited by 220
Van Cutsem, E., Kang, Y., Chung, H., Sawaki, A., Lordick, F., Hill, J., Lehle, M., Feyereislova, A., & Bang, Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.lba4509 · Cited by 203
Park, B.-W., Zhang, H.-T., Wu, C., Berezov, A., Zhang, X., Dua, R., Wang, Q., Kao, G., O'Rourke, D. M., Greene, M. I., et al. (2000) · Nature Biotechnology · doi:10.1038/72651 · Cited by 199
Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandström, M., Nilsson, F. Y., Wennborg, A., Abrahmsén, L., & Feldwisch, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2887 · Cited by 193
An attractive force in metastasis
Liotta, L. A. (2001) · Nature · doi:10.1038/35065180 · Cited by 185
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
Ziada, A., Barqawi, A., Glode, L. M., Varella‐Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M., Chen, L., & Crawford, E. D. (2004) · The Prostate · doi:10.1002/pros.20065 · Cited by 181
The role of overexpressed HER2 in transformation
Neve, R. M., Lane, H. A., & Hynes, N. E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s9 · Cited by 173
Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging
Lee, S. B., Hassan, M., Fisher, R., Chertov, O., Chernomordik, V., Kramer-Marek, G., Gandjbakhche, A., & Capala, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4076 · Cited by 171
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
Reid, A. H. M., Vidal, L., Shaw, H. M., & Bono, J. S. D. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.007 · Cited by 168
CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo
Lapteva, N., Yang, A.-G., Sanders, D. E., Strube, R. W., & Chen, S.-Y. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700770 · Cited by 167
HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy
Alexis, F., Basto, P., Levy‐Nissenbaum, E., Radovic‐Moreno, A. F., Zhang, L., Pridgen, E., Wang, A. Z., Marein, S. L., Westerhof, K., Molnar, L. K., et al. (2008) · ChemMedChem · doi:10.1002/cmdc.200800122 · Cited by 164
HER2-Positive Breast Cancer: Current and Future Treatment Strategies
Engel, R. H., & Kaklamani, V. (2007) · Drugs · doi:10.2165/00003495-200767090-00006 · Cited by 157
Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells
Shadidi, M., & Sioud, M. (2002) · The FASEB Journal · doi:10.1096/fj.02-0280fje · Cited by 156
ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase
Hellyer, N. J., Cheng, K., & Koland, J. G. (1998) · Biochemical Journal · doi:10.1042/bj3330757 · Cited by 144
Self-citationChinni, S. R., Yamamoto, H., Dong, Z., Sabbota, A. L., Bonfil, R. D., & Cher, M. L. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0117 · Cited by 141
Faltus, T., Yuan, J., Zimmer, B., Krämer, A., Loibl, S., Kaufmann, M., & Strebhardt, K. (2004) · Neoplasia · doi:10.1593/neo.04313 · Cited by 140
Clinical significance of vascular endothelial growth factor‐C (VEGF‐C) in breast cancer
Kinoshita, J., Kitamura, K., Kabashima, A., Saeki, H., Tanaka, S., & Sugimachi, K. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010692132669 · Cited by 140
Choudhury, A., Charo, J., Parapuram, S. K., Hunt, R. C., Hunt, D. M., Seliger, B., & Kiessling, R. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11497 · Cited by 139
Overexpression of HER-2 in ovarian carcinomas.
Hellström, I., Goodman, G. E., Pullman, J., Yang, Y., & Hellström, K. E. (2001) · PubMed · Cited by 136
King, D., Dubowchik, G. M., Mastalerz, H. A., Willner, D., Hofstead, S. J., Firestone, R. A., Lasch, S. J., & Trail, P. A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020149g · Cited by 135
Tan, M., Lan, K., Yao, J., Lu, C., Sun, M., Neal, C. L., Lü, J., & Yu, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2747 · Cited by 129
Unraveling the Biologic and Clinical Complexities of HER2
Park, J. W., Neve, R. M., Szöllõsi, J., & Benz, C. C. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.047 · Cited by 123
Petrelli, N. J., Winer, E. P., Brahmer, J., Dubey, S., Smith, S., Thomas, C., Vahdat, L. T., Obel, J., Vogelzang, N., Markman, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6171 · Cited by 121
Localization of a Major Receptor-Binding Domain for Epidermal Growth Factor by Affinity Labeling
Lax, I., Burgess, W. H., Bellot, F., Ullrich, A., Schlessinger, J., & Givol, D. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.4.1831 · Cited by 121
Yang, G. S., Cai, K. Q., Thompson-Lanza, J. A., Bast, R. C., & Liu, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311153200 · Cited by 120
Klos, K. S., Zhou, X., Lee, S., Zhang, L., Yang, W., Nagata, Y., & Yu, D. (2003) · Cancer · doi:10.1002/cncr.11656 · Cited by 111
A Peptide Conjugate of Vitamin E Succinate Targets Breast Cancer Cells with High ErbB2 Expression
Wang, X., Birringer, M., Dong, L., Vepřek, P., Low, P., Swettenham, E., Stantic, M., Yuan, L., Zobalová, R., Wu, K., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2480 · Cited by 107
Liu, Y., Majumder, S., McCall, W., Sartor, C. I., Mohler, J. L., Gregory, C. W., Earp, H. S., & Whang, Y. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4292 · Cited by 107
Shibata, T., Ochiai, A., Kanai, Y., Akimoto, S., Gotoh, M., Yasui, N., Machinami, R., & Hirohashi, S. (1996) · PubMed · Cited by 106
Pegram, M. D., & Reese, D. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70124-3 · Cited by 105
Margulis, A. R., Zhang, W., Alt‐Holland, A., Crawford, H. C., Fusenig, N. E., & Garlick, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3399 · Cited by 95
Pharmaceutical Perspectives of Cancer Therapeutics
Lu, Y. W., & Mahato, R. I. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6 · Cited by 93
Self-citationPils, D., Pinter, A., Reibenwein, J., Alfanz, A., Horak, P., Schmid, B. C., Hefler, L., Horvat, R., Reinthaller, A., Zeillinger, R., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603581 · Cited by 90
Schroeder, J. A., Adriance, M. C., McConnell, E. J., Thompson, M. C., Pockaj, B. A., & Gendler, S. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201975200 · Cited by 88
Manders, P., Beex, L. V. A. M., Tjan‐Heijnen, V. C. G., Span, P. N., & Sweep, F. C. G. J. (2003) · Cancer · doi:10.1002/cncr.11764 · Cited by 83
Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells
Li, X., Stuckert, P., Bosch, I., Marks, J. D., & Marasco, W. A. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700337 · Cited by 77
Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery
Hayes, M. E., Drummond, D. C., Kirpotin, D. B., Zheng, W. W., Noble, C. O., Park, J. W., Marks, J. D., Benz, C. C., & Hong, K. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302699 · Cited by 77
Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer
Cameron, D., & Stein, S. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1156 · Cited by 76
HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
Spector, N. L., Xia, W., El‐Hariry, I. A., Yarden, Y., & Bacus, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1652 · Cited by 73
Li, J., Kim, J. P., Shen, H. C., Clark, P. E., Tilley, W. D., & Coetzee, G. A. (2003) · PubMed · Cited by 72
HER-2/neu Is Rate-limiting for Ovarian Cancer Growth
Juhl, H. H., Downing, S. G., Wellstein, A., & Czubayko, F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.47.29482 · Cited by 70
Jia, L., Zhang, L.-H., Yu, C.-J., Zhao, J., Xu, Y., Gui, J.-H., Jin, M., Ji, Z., Wen, W.-H., Wang, C.-J., et al. (2003) · PubMed · Cited by 69
Holloway, J. N., Murthy, S., & El‐Ashry, D. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0048 · Cited by 65
Ongoing adjuvant trials with trastuzumab in breast cancer
TAN, A., & Swain, S. M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.008 · Cited by 61
Herceptin-Geldanamycin Immunoconjugates
Mandler, R., Kobayashi, H., Hinson, E. R., Brechbiel, M. W., & Waldmann, T. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2485 · Cited by 60
Fantin, V. R., Berardi, M. J., Babbe, H., Ventosa-Michelman, M., Manning, C. M., & Leder, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0395 · Cited by 57
Belousova, N., Mikheeva, G., Gelovani, J. G., & Krasnykh, V. N. (2007) · Journal of Virology · doi:10.1128/jvi.01896-07 · Cited by 56
Small, E. S., Bok, R., Reese, D., Sudilovsky, D., & Frohlich, M. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90159-9 · Cited by 55
Mullen, P., Cameron, D., Hasmann, M., Smyth, J. F., & Langdon, S. P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0401 · Cited by 55
Telesco, S., & Radhakrishnan, R. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2008.12.3912 · Cited by 50
Im, S., Kim, J.-S., Gomez‐Manzano, C., Fueyo-Margareto, J., Liu, T. J., Cho, M. S., Seong, C.-M., Lee, S. N., Hong, Y. K., & Yung, W. K. A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1734 · Cited by 49
Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF
Tai, W., Qin, B., & Cheng, K. (2010) · Molecular Pharmaceutics · doi:10.1021/mp9002514 · Cited by 48
Self-citationBeeram, M., Burris, H. A., Modi, S., Birkner, M., Girish, S., Tibbitts, J., Holden, S. N., Lutzker, S. G., & Krop, I. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1028 · Cited by 48
Newton, J., & Deutscher, S. L. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-77496-9_7 · Cited by 47
2008 Gastrointestinal Cancers Symposium
Fricker, J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70054-8 · Cited by 46
Cho, H.-M., Rosenblatt, J. D., Kang, Y., Iruela‐Arispe, M. L., Morrison, S. L., Penichet, M. L., Kwon, Y., Kim, T., Webster, K. A., Nechushtan, H., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0321 · Cited by 46
Siwak, D. R., Tari, A. M., & Lopez‐Berestein, G. (2002) · PubMed · Cited by 46
HER-2-Positive Breast Cancer: Hope Beyond Trastuzumab
Bartsch, R., Wenzel, C., Zielinski, C. C., & Steger, G. G. (2007) · BioDrugs · doi:10.2165/00063030-200721020-00001 · Cited by 42
Lissoni, P., Rovelli, F., Malugani, F., Brivio, F., Fumagalli, L. A. M., & Gardani, G. (2003) · The International Journal of Biological Markers · doi:10.1177/172460080301800209 · Cited by 40
Hayes, M. E., Drummond, D. C., Hong, K., Zheng, W. W., Khorosheva, V. A., Cohen, J. A., Noble, Park, J. W., Marks, J. D., Benz, C. C., et al. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060040v · Cited by 36
Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases
Hayes, M. E., Drummond, D. C., Hong, K., et al. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.03.020 · Cited by 35
Guillemard, V., Nedev, H. N., Berezov, A., Murali, R., & Saragovi, H. U. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.351 · Cited by 34
Finkenzeller, G., Weindel, K., Zimmermann, W., Westin, G., & Marmé, D. (2004) · Angiogenesis · doi:10.1023/b:agen.0000037332.66411.f0 · Cited by 31
Roh, H., Hirose, C. B., Boswell, C., Pippin, J. A., & Drebin, J. A. (1999) · Surgery · doi:10.1016/s0039-6060(99)70186-8 · Cited by 26
Roh, H., Pippin, J. A., Boswell, C., & Drebin, J. A. (1998) · Journal of Surgical Research · doi:10.1006/jsre.1998.5353 · Cited by 26
Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods
Nakajima, H., Mizuta, N., Sakaguchi, K., Fujiwara, I., Yoshimori, A., Takahashi, S., Takasawa, R., & Tanuma, S.-I. (2007) · Breast Cancer · doi:10.1007/s12282-007-0018-8 · Cited by 25
HER2/HER3 heterodimers in prostate cancer
Freeman, M. R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.018 · Cited by 25
HER-dimerization inhibitors: evaluating pertuzumab in women's cancers
Kristjánsdóttir, K., & Dizon, D. S. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903514090 · Cited by 16
RNA Interference for Cancer Therapy
Cheng, K., & Qin, B. Y. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_13 · Cited by 6
Self-citation
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Liang, G., Zhu, Y., Ali, D. J., Tian, T., Xu, H., Si, K., Sun, B., Chen, B., & Xiao, Z. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0563-2 · Cited by 619
Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy
Zhong, Y., Meng, F., Deng, C., & Zhong, Z. (2014) · Biomacromolecules · doi:10.1021/bm5003009 · Cited by 541
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Metadata
- Authors
- Tai, W., Mahato, R., & Cheng, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2010-09-15
- Volume
- 146
- Issue
- 3
- Pages
- 264-275
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W1987362747
- Cited by
- 555
- References
- 125
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.